Nicholas Short
Overview
Explore the profile of Nicholas Short including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rafaeli N, Costa D, Ledesma C, Jain N, Tewari P, Khouri I, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39955258
No abstract available.
2.
Shatila M, Machado A, Shah J, Rivera A, Naz S, Glombicki S, et al.
Target Oncol
. 2025 Feb;
PMID: 39904838
Background: Stem cell transplantation (SCT) and immune checkpoint inhibitors (ICIs) are both used in the treatment of hematological malignancies. There may be an overlap in patient exposure to both treatments....
3.
Kawedia J, Rausch C, Liu X, Qiao W, DiNardo C, Daver N, et al.
Am J Hematol
. 2025 Jan;
100(4):740-743.
PMID: 39873236
No abstract available.
4.
Montalban-Bravo G, Jabbour E, Chien K, Hammond D, Short N, Ravandi F, et al.
Leuk Res
. 2024 May;
142:107518.
PMID: 38744144
We conducted a phase 1 study evaluating 3 dose levels of quizartinib (30 mg, 40 mg or 60 mg) in combination with azacitidine for HMA-naïve or relapsed/refractory MDS or MDS/MPN...
5.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, et al.
Lancet Haematol
. 2024 Mar;
11(4):e287-e298.
PMID: 38548404
Background: Patients with acute myeloid leukaemia have high rates of relapse, especially if they are unable to complete standard consolidation strategies or allogeneic haematopoietic stem-cell transplantation (HSCT). The phase 3...
6.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, et al.
Lancet Haematol
. 2024 Mar;
11(4):e276-e286.
PMID: 38452788
Background: Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of...
7.
Modak R, de Oliveira Rebola K, McClatchy J, Mohammadhosseini M, Damnernsawad A, Kurtz S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2245-2259.
PMID: 38451486
Purpose: Emerging evidence underscores the critical role of extrinsic factors within the microenvironment in protecting leukemia cells from therapeutic interventions, driving disease progression, and promoting drug resistance in acute myeloid...
8.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Yilmaz M, Short N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Mar;
24(6):375-381.
PMID: 38431521
Background: The outcome of patients with acute promyelocytic leukemia (APL) has improved significantly since the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) as APL therapies. The optimal...
9.
Montalban-Bravo G, Rodriguez-Sevilla J, Swanson D, Kanagal-Shamanna R, Hammond D, Chien K, et al.
Leukemia
. 2024 Feb;
38(5):1178-1181.
PMID: 38418609
No abstract available.
10.
Bataller A, DiNardo C, Bazinet A, Daver N, Maiti A, Borthakur G, et al.
Am J Hematol
. 2024 Feb;
99(4):792-796.
PMID: 38361282
Incidence of potential targetable genetic abnormalities by age in AML.